Aberrant cytogenetic evolution pattern of Philadelphia-positive chronic myeloid leukemia treated with interferon-α

Leukemia

Volumn 10, Issue 7, 1996, Pages 1134-1138

  Johansson, B ^a   Fioretos, T ^a   Billstrom R ^a   Mitelman, F ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic myeloid leukemia; Interferon; Secondary chromosomal abnormalities

Indexed keywords

ALPHA INTERFERON; BUSULFAN; HYDROXYUREA; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHROMOSOME 13Q; CHROMOSOME 7P; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; INTERSTITIAL CHROMOSOME DELETION; MALE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; BONE MARROW TRANSPLANTATION; CHILD; CHROMOSOME ABERRATION; COMPARATIVE STUDY; GENETICS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED;

EID: 0029666313     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
2. Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987; 83: 445-454.
3. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin Hematol 1988; 25: 20-34.
4. Mitelman F. The cytogenetic scenario of chronic myeloid leukemia. Leuk Lymphoma 1993; 11: 11-15.
5. Heim S, Mitelman F. Cancer Cytogenetics, 2nd edn. Wiley-Liss: New York, 1995.
6. Ruff P, Saragas E, Poulos M, Weaving A. Patterns of clonal evolution in transformed chronic myeloid leukemia. Cancer Genet Cytogenet 1995; 81: 182-185.
7. Mitelman F, Levan G, Nilsson PG, Brandt L. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer 1976; 18: 24-30.
8. Prigogina EL, Fleischman EW, Volkova MA, Frenkel MA. Chromosome abnormalities and clinical and morphologic manifestations of chronic myeloid leukemia. Hum Genet 1978; 41: 143-156.
9. O'Malley FM, Garson OM. Chronic granulocytic leukemia: correlation of blastic transformation type with karyotypic evolution. Am J Hematol 1985; 20: 313-323.
10. Parreira L, Kearney L, Rassool F, Babapulle VB, Matutes E, Parreira A, Tavares de Castro J, Goldman JM, Catovsky D. Correlation between chromosomal abnormalities and blast phenotype in the blast crisis of Ph-positive CGL. Cancer Genet Cytogenet 1986; 22: 29-34.
11. Alimena G, De Cuia MR, Diverio D, Gastaldi R, Nanni M. The karyotype of blastic crisis. Cancer Genet Cytogenet 1987; 26: 39-50.
12. Diez-Martin JL, Dewald GW, Pierre RV. Possible cytogenetic distinction between lymphoid and myeloid blast crisis in chronic granulocytic leukemia. Am J Hematol 1988; 27: 194-203.
13. Bernstein R, Gale RP. Do chromosome abnormalities determine the type of acute leukemia that develops in CML? Leukemia 1990; 4: 65-68.
14. Chang H-J, Tien H-F, Wang C-H, Chuang S-M, Chen YC, Shen M-C, Lin D-T, Lin K-H. Comparison of clinical and biologic features between myeloid and lymphoid transformation of Philadelphia chromosome positive chronic myeloid leukemia. Cancer Genet Cytogenet 1993; 71: 87-93.
15. Murakami T, Ohyashiki K, Ohyashiki JH, Kawakubo K, Tauchi T, Nakazawa S, Kimura N, Toyama K. Cytogenetic and immunogenotypic alterations of blast crisis cells in chronic myelogenous leukemia independently linked to immunophenotypic expression. Cancer Genet Cytogenet 1994; 72: 48-54.
16. Nanjangud G, Kadam PR, Saikia T, Bhisey AN, Kumar A, Gopal R, Chopra H, Nair CN, Advani SH. Karyotypic findings as an independent prognostic marker in chronic myeloid leukemia blast crisis. Leukemia Res 1994; 18: 385-392.
17. Pedersen-Bjergaard J, Johansson B, Philip P. Translocation (3;21)(q26;q22) in therapy-related myelodysplasia following drugs targeting DNA-topoisomerase II combined with alkylating agents, and in myeloproliferative disorders undergoing spontaneous leukemic transformation. Cancer Genet Cytogenet 1994; 76: 50-55.
18. Mitelman F. Catalog of Chromosome Aberrations in Cancer, 5th edn. Wiley-Liss: New York, 1994.
19. Alimena G, Brandt L, Dallapiccola B, Mitelman F, Nilsson PG. Secondary chromosome changes in chronic myeloid leukemia: relation to treatment. Cancer Genet Cytogenet 1979; 1: 79-85.
20. Swolin B, Weinfeld A, Westin J, Waldenström J, Magnusson B. Karyotypic evolution in Ph-positive chronic myeloid leukemia in relation to management and disease progression. Cancer Genet Cytogenet 1985; 18: 65-79.
21. Calabrese G, Di Bartolomeo P, Stuppia L, Franchi PC, Parruti G, Ciancarelli M, Angrilli F, Geraci L, Palka G. Cytogenetics in patients with chronic myelogenous leukemia treated with bone marrow transplantation. Cancer Genet Cytogenet 1989; 41: 49-59.
22. Sessarego M, Frassoni F, Defferrari R, Bacigalupo A, Miceli S, Mareni C, Ajmar F. Cytogenetic follow-up after bone marrow transplantation for Philadelphia-positive chronic myeloid leukemia. Cancer Genet Cytogenet 1989; 42: 253-261.
23. Sessarego M, Frassoni F, Defferrari R, Bacigalupo A, Fugazza G, Mareni C, Bruzzone R, Dejana A, Ajmar F. Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogenic bone marrow transplantation. Cancer Genet Cytogenet 1991; 57: 69-78.
24. Zaccaria A, Rosti G, Testoni N, Santucci MA, Tassinari A, Celso B, Buzzi M, Miggiano MC, Tura S. Cytogenetic events after bone marrow transplantation for Philadelphia chromosome positive chronic myeloid leukemia. Leukemia Res 1991; 15: 289-296.
25. Bilhou-Nabera C, Bernard P, Marit G, Viard F, Gharbi MJ, Wen Z, Lacombe F, Braustet A, Reiffers J. Serial cytogenetic studies in allografted patients with chronic myeloid leukemia. Bone Marrow Transplant 1992; 9: 263-268.
26. Johansson B, Mertens F, Mitelman F. Geographic heterogeneity of neoplasia-associated chromosome aberrations. Genes Chromosom Cancer 1991; 3: 1-7.
27. ISCN (1995). An International System for Human Cytogenetic Nomenclature. Mitelman F (ed). S Karger: Basel, 1995.
28. Höglund M, Johansson B, Pedersen-Bjergaard J, Marynen P, Mitelman F. Molecular characterization of 12p abnormalities in hematologic malignancies: Deletion of KIP1, rearrangement of TEL, and amplification of CCND2. Blood 1996; 87: 324-330.
29. Nogueira-Costa R, Spitzer G, Khorana S, Pham Q, Kantarjian HM, Manning JT, Ordonez NC, Dicke KA. T-cell involvement in benign phase chronic myelogenous leukemia. Leukemia Res 1986; 10: 1433-1439.
30. Huret JL, Schoenwald M, Brizard A, Guilhot F, Vilmer E, Tanzer J. Chromosome 6p rearrangements appear to be secondary changes in various haematological malignancies. Leukemia Res 1989; 13: 819-824.
31. Claxton D, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU, Talpaz M. Alpha Interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia. Acta Haematol 1990; 83: 149-151.
32. Hild F, Fonatsch C. Cytogenetic peculiarities in chronic myelogenous leukemia. Cancer Genet Cytogenet 1990; 47: 197-217.
33. De la Chica RA, Pueyo JM, Matilla A, Labrana X, Padron F, Guerras L, Sole F, Plaja A. t(3;14)(q26;q11) associated with megakaryoblastic transformation of chronic myeloid leukemia. Cancer Genet Cytogenet 1991; 55: 133-134.
34. BCR-ABL myelogenous leukemia may correlate with disease progression. Leukemia 1991; 5: 191-195.
35. 1-positive chronic myelocytic leukemia. Genes Chromosom Cancer 1992; 4: 269-270.
36. Ferro MR, Cabello P, Garcia-Sagredo JM, Resino M, San Roman C, Larana JG. t(16;21) in a Ph positive CML. Cancer Genet Cytogenet 1992; 60: 210-211.
37. 1-positive chronic myelogenous leukemia patient previously treated with α-interferon. Leukemia 1992; 6: 738-741.
38. Russell M, Thompson F, Spier C, Taetle R. Expression of the EVI1 gene in chronic myelogenous leukemia in blast crisis. Leukemia 1993; 7: 1654-1657.
39. Jonveaux P, Derré J, Berger R. Whole arm translocation t(17;18): a non-random abnormality of myeloid cell proliferation. Leukemia 1993; 7: 1987-1989.
40. Ambrosetti A, Krampera M, Veneri D, Meneghini V, Aprili F, Martinelli G, Pizzolo G, Perona G. Early lymphoid blastic crisis following major karyotypic conversion in a chronic myeloid leukemia patient treated with interferon-a. Int J Clin Lab Res 1994; 24: 58-59.
41. Christodoulidou F, Silver RT, Macera MJ, Verma RS. Unusual clonal evolution during blast crisis of chronic myeloid leukemia (CML). Eur J Cancer 1994; 30A: 1040-1041.
42. Nakagawa H, Fujii H, Nakai H, Inazawa J, Misawa S. Myelomonocytic crisis with t(5;17) and a p53 mutation in a patient with chronic myelogenous leukemia. Am J Hematol 1994; 45: 335-340.
43. Najfeld V, Hauschildt B, Scalise A, Gattani A, Patel R, Ambinder EP, Silverman LR. Jumping translocations in leukemia. Leukemia 1995; 9: 634-639.
44. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queißer W, Löffler H, Hochhaus A, Heinze B, Georgii A, Bartram CR, Grießhammer M, Bergmann L, Essers U, Falge C, Queißser U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeberg UR, Käbisch A, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges FJ, Schmid L, Brockhaus W, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow PV, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H, the German CML Study Group. Randomized comparison of interferon-α with busulfan and hydroxyurea in chronic myelogenous leukemia. Blood 1994; 84: 4064-4077.
45. Talpaz M. Use of Interferon in the treatment of chronic myelogenous leukemia. Semin Oncol 1994; 21: 3-7.
46. Allan NC, Richards SM, Shepherd PCA, on behalf of the UK Medical Research Council's Working parties for Therapeutic Trials in Adult Leukaemia. UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
47. Spencer A, O'Brien SG, Goldman JM. Options for therapy in chronic myeloid leukaemia. Br J Haematol 1995; 91: 2-7.
48. Wetzler M, Kantarjian H, Kurzrock R, Talpaz M. Interferon-α therapy for chronic myelogenous leukemia. Am J Med 1995; 99: 402-411.
49. Gresser I. Antitumour effects of interferons: past, present and future. Br J Haematol 1991; 79: 1-5.
50. Galvani DW, Cawley JC. Mechanism of action of α interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors. Br J Haematol 1989; 73: 475-479.
51. Gronthos S, To LB, Haylock DN, Juttner CA. A differential sensitivity to recombinant human interferon-alpha 2a between normal and chronic myeloid leukaemic peripheral blood granulocytemacrophage colony-forming units. Leukemia Res 1992; 16: 153-158.
52. Meseri A, Delwail V, Brizard A, Lecron JC, Pelletier D, Guilhot F, Tanzer J, Goube de Laforest P. Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with α-interferon. Br J Haematol 1993; 83: 218-222.
53. Aulitzky WE, Peschel C, Schneller F, Huber C. Biotherapy of chronic myelogenous leukemia. Ann Hematol 1995; 70: 113-120.
54. Bhatia R, McGlave PB, Verfaillie CM. Treatment of marrow stroma with interferon-α restores normal β1 integrin-dependent adhesion of chronic myelogenous leukemia hematopoietic progenitors. Role of MIP-1α. J Clin Invest 1995; 96: 931-939.
55. Majlis A, Smith TL, Talpaz M, O'Brien S, Rios MB, Kantarjian HM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996; 14: 196-203.
56. Hild F, Freund M, Fonatsch C. Chromosomal aberrations during interferon therapy for chronic myelogenous leukemia. New Engl J Med 1991; 325: 132.
57. Bilhou-Nabera C, Marit G, Devianne I, Viard F, Salzes S, Montastruc M, Renoux M, Broustet A, Reiffers J, Bernard P. A second case of trisomy 8 in Philadelphia chromosome (Ph)-negative cells during the course of Ph-positive chronic myelocytic leukemia. Genes Chromosom Cancer 1993; 6: 255-256.
58. Ariyama T, Inazawa J, Uemura Y, Kakazu N, Maekawa T, Urase F, Irimajiri K, Horiuchi A, Nakamura Y, Abe T. Clonal origin of Philadelphia chromosome negative cells with trisomy 8 appearing during the course of α-interferon therapy for Ph positive chronic myelocytic leukemia. Cancer Genet Cytogenet 1995; 81: 20-23.
59. Mitelman F, Brandt L, Nilsson PG. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphocytic leukemia. Blood 1978, 52: 1229-1237.
60. Johansson B, Mertens F, Heim S, Kristoffersson U, Mitelman F. Cytogenetics of secondary myelodysplasia (sMDS) and acute non-lymphocytic leukemia (sANLL). Eur J Haematol 1991; 47: 17-27.
61. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 1994; 83: 2780-2786.
62. Kampmeier P, Spielberger R, Dickstein J, Mick R, Golomb H, Vardiman JW. Increased incidence of second neoplasms in patients treated with interferon α 2b for hairy cell leukemia: a clinicopathologic assessment. Blood 1994; 83: 2931-2938.